Xeljanz® use for RA on the rise (but so is its discontinuation rate)

Nearly half of Xeljanz® users discontinue the costly RA drug after one year

February 9, 2017

Prime research shows nearly half of Xeljanz® users discontinue the costly rheumatoid arthritis (RA) drug after one year

The FDA approved Tofacitinib (Xeljanz®) for people with RA who have an inadequate response to methotrexate. The study found that one in 10 members were potentially not following guidelines to use tofacitininb as second line therapy. Additionally, 44 percent of members discontinued the drug by one year. RA is a chronic condition that needs ongoing treatment; this study show there is opportunity for improvement. Plan sponsors should develop care and utilization management programs that encourage adherence and cost-effective treatment strategies.

Tofacitinib (Xeljanz®) Utilization Patterns and Persistency Among 4.4 Million Continuously Enrolled Commercially Insured Members Over Four Years (Fall 2016)

Related news


March 24, 2023

Look for Prime + Magellan Rx at AMCP 2023

Dr. Prerak Parikh (far left) and Dr. Sneha Sharma (far right) discuss trends…


March 23, 2023

Top female finance executive encourages DEI narrative

Over the past 30 years women’s careers in finance have seen significant progress,…


March 21, 2023

Top 10 acronyms in drug pipeline content, Part 2

News about biosimilars is everywhere. Sometimes you just need the basics. This four-part…